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Abstract: 
We analyzed RNA gene expression in neurons from 16 cases in four categories, HIV associated dementia with HIV encephalitis (HAD/HIVE), HAD alone, HIVE 
alone, and HIV-1-positive (HIV+)with neither HAD nor HIVE. We produced the neurons by laser capture microdissection (LCM) from cryopreserved globus 
pallidus. Of 55,000 gene fragments analyzed, expression of 197 genes was identified with significance (p = 0.005).We examined each gene for its position in the 
human genome and found a non-stochastic occurrence for only seven genes, on chromosome 22. Six of the seven genes were identified, CSNK1E (casein kinase 1 
epsilon), DGCR8 (Di George syndrome critical region 8), GGA1 (Golgi associated gamma adaptin ear containing ARF binding protein 1), MAPK11 (mitogen 
activated protein kinase 11), SMCR7L (Smith-Magenis syndrome chromosome region candidate 7-like), andTBC1D22A (TBC1 domain family member 22A). Six 
genes (CSNK1E, DGCR8, GGA1, MAPK11, SMCR7L, and one unidentified gene) had similar expression profiles across HAD/HIVE, HAD, and HIVE vs. HIV+ 
whereas one gene (TBC1D22A) had a differing gene expression profile across these patient categories. There are several mental disease-related genes including 
miRNAs on chromosome 22 and two of the genes (DGCR8 and SMCR7L) identified here are mental disease-related. We speculate that dysregulation of gene 
expression may occur through mechanisms involving chromatin damage and remodeling. We conclude that the pathogenesis of NeuroAIDS involves dysregulation 
of expression of mental disease-related genes on chromosome 22 as well as additional genes on other chromosomes. The involvement of these genes as well as 
miRNA requires additional investigation since numerous genes appear to be involved.  
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Background: 
NeuroAIDS and HAD: 
The involvement of the CNS in HIV-related disease generally has been termed 
NeuroAIDS. HIV associated dementia (HAD) and minor cognitive motor 
disorder (MCMD) were terms used as well. The presence of infiltrating 
macrophages and activated microglial containing HIV-1, termed HIV 
encephalitis (HIVE) is part of the neuropathological substrate of this disease. In 
addition, neuronal damage is a key end-point in the disease process during and 
subsequent to HIV-1 brain infection [1, 2, 3]. Since the advent of HAART, a 
new term, HIV-associated neurocognitive disorders (HAND) has come to the 
fore. Due to HAART, the incidence of motor abnormalities and cognitive 
impairment of HAD and HIVE decreased although their prevalence has 
increased. Factors possibly associated with these changes may include viral 
mutations and patient longevity [3, 4, 5].  In the results reported here, the 
patients are from studies in an earlier time-period, prior to the implementation 
of HAND as a diagnostic entity [6]. 
 
NeuroAIDS Gene expression and Neurogenetics: 
The neurogenetics of NeuroAIDS has been under study for several years. A 
variety of genes, largely immune-related, but also those related to 
neurobiological functioning, have been found to be associated with 
neurocognitive outcomes and risk of HAD, although not all findings have been 
replicated [7, 8, 9]. This lack of consistency may be due to the difficulty in 
classifying NeuroAIDS neurocognitive disorders and the heterogeneous 
mechanisms leading to neurocognitive dysfunction. Gene expression in 
NeuroAIDS was studied for many years and has been previously reviewed [3, 
6, 10, 11, 12]. In addition, a recent study produced gene expression data from 
Globus pallidus neurons purified by LCM from patients with HAD/HIVE, BIOINFORMATION  open access 
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HAD, HIVE, and HIV+ without HAD or HIVE [6]. A variety of inflammatory 
mediators and signaling pathway genes were implicated. These studies have 
yielded widely variable findings that will require additional efforts to integrate. 
The use of high throughput microarrays, for example, provides expression data 
for tens of thousands of probes. As such, methods for biologically relevant 
interpretation of these data have come into use, drawing largely from the 
burgeoning fields of systems biology and bioinformatics.  
 
Materials & Methodology: 
Brain Tissue, LCM, RNA Purification, and Gene Expression analysis: 
Brain Tissue was obtained and LCM, RNA purification, and gene expression 
analysis were done as previously described [6, 13]. Autopsied cryopreserved 
brain tissue was obtained from several tissue banks in the NIH sponsored 
National NeuroAIDS Tissue Consortium (NNTC) [14, 15]. Neurons were 
microdissected, using LCM from Globus pallidus from HIV-positive 
individuals in four categories HAD/HIVE, HAD alone, HIVE alone, and HIV+ 
only. RNA was then purified from microdissected neurons, amplified, and gene 
expression analysis performed [6, 13]. Expression of 55,000 genes was 
analyzed using CodeLink Human Whole Genome Bioarrays [16]. 
 
Statistical analysis: 
CodeLink Expression Analysis software (GE Healthcare) was used,as 
previously described, to process the scanned images from the arrays [6]. 
GeneSpring software (Agilent Technologies) was then used to generate the 
gene expression data including quality control gene analyses [6].  Gene 
identification was based on urls [17, 18]. One-Way Analysis of Variance 
(ANOVA) was used to identify genes with expression that was statistically 
significant (at p ≤ 0.005) across the four groups HAD/HIVE, HAD alone, 
HIVE alone, and HIV+ only, as previously described [6]. Pair-wise student t 
tests were then performed using the MSE (mean square error) term from the 
ANOVA, to test the simple effects of HAD/HIVE vs. control, HAD alone vs. 
control, and HAD alone vs. control for each selected gene [6]. In addition, the 
selected genes were identified as to their location on each of the 23 human 
chromosomes. (The Y chromosome was not considered). The expected number 
of genes per chromosome was calculated by multiplying the total of ascribed 
genes by the proportion of the total number of genes with known chromosome 
locations on that particular chromosome. The allocation of genes to each 
chromosome was then tested for randomness by a single degree of freedom Chi 
Square test and Bonferroni-adjusted (p = .05/23 = 0.0023). 
 
Pathway analysis: 
Gene Network Central PRO at was used to generate gene interaction and 
pathway figures [19].  
 
 
Figure 1: Effect Size [(Condition- control)/ Std. Dev.] of genes allocated to 
Chromosome 22. 
 
Results: 
190 genes, previously shown to be significantly expressed across HAD/HIVE, 
HAD alone, and HIVE alone vs. HIV+ only, had known locations on 23 human 
chromosomes. The result of gene allocation to chromosome is shown in Table 
1 (see Supplementary material). Only chromosome 22 demonstrated a non-
stochastic number of ascribed genes (p ≤ 0.0001).Six genes identified on 
chromosome 22 are CSNK1E (casein kinase 1 epsilon), DGCR8 (Di George 
syndrome critical region 8), GGA1 (Golgi associated gamma adapt in ear 
containing ARF binding protein 1), MAPK11 (mitogen activated protein kinase 
11), SMCR7L (Smith-Magenis syndrome chromosome region candidate 7-
like), andTBC1D22A (TBC1 domain family member 22A). One gene ascribed 
to chromosome 22 was unidentified. The array responses of the seven genes 
allocated to chromosome 22 across HAD/HIVE, HAD, and HIVE vs. HIV+, 
expressed as the effect size ratio (condition mean-control mean)/(standard 
deviation) are shown in Figure 1. Six of the genes show very similar 
responses, while the seventh shows a different response from the other six. The 
six genes with similar expression profiles were CSNK1E, DGCR8, GGA1, 
MAPK11, SMCR7L, and the single unidentified gene. One gene, TBC1D22A, 
had a differing gene expression profile across the patient categories compared 
to controls. Figure 2 shows the molecular pathway network connections 
among the six identified genes located on chromosome 22. This pathway 
analysis shows the six genes interconnected with 69 additional nearest neighbor 
gene interactions. Table 2 (see Supplementary material) shows CodeLink 
and GE IDs, aliases, chromosome 22 band locations, and basic functions of the 
six identified genes as well as the interconnecting genes.  
 
 
Figure 2: Pathways interconnecting 6 genes CSNK1E, DGCR8, GGA1, 
MAPK11, SMCR7L, and TBC1D22A as well as 69 additional nearest neighbor 
gene interactions. 
 
Discussion: 
A plethora of genes has already been implicated in the pathogenesis of 
neurological and neuropsychiatric disease that result from HIV-1 brain 
infection. Recent studies implicate additional genes with progress and use of 
newer techniques. Due to the complexity and prolonged course of HIV-1 
associate brain disease, it should not be surprising that so many genes may be 
involved. We recently identified 150 genes involved in pathogenesis of 
HAD/HIVE, HAD alone, HIVE alone compared to only HIV-1 infection. The 
HAD/HIVE, HAD alone, and HIVE alone gene expression means for all of 
these genes are significantly different from the HIV+ control [6]. Here, we 
show that of seven genes that were associated with chromosome 22, two of the 
genes are mental disease-related. Moreover, there are additional mental 
disease-related genes on this chromosome.  
 
Many additional genes interconnect the six genes that we identified on 
chromosome 22 and 69 such genes are shown in Figure 2. Four of the 
additional interconnection genes are also on chromosome 22, AP1B1, GRAP, 
CRKL, and POLR2D. AP1B1 (adapter-related protein complex 1, beta 1 
subunit), forms complexes that mediate both the recruitment of clathrin to 
membranes and the recognition of sorting signals within the cytosolic tails of 
transmembrane cargo molecules. GRAP (GRB2-related adapter protein), 
couples signals from receptor and cytoplasmic tyrosine kinases to the Ras 
signaling pathway. CRKL (V-crk sarcoma virus CT10 oncogene homolog 
(avian)-like), participates in intra-cellular signal transduction. POLR2D 
(polymerase (RNA) II (DNA directed) polypeptide D), is a component of RNA 
polymerase. Thus, dysfunction and pathogenesis for the neurons caused by the 
dysregulation of the six genesis further exacerbated by the dysregulation of 
networks involving the four additional interconnection genes on this small 
chromosome.  
 
Chromosome 22 is the second smallest chromosome and has several mental 
disease-related genes in addition to the two that we identified in our study that 
are on this chromosome. The COMT gene is located at 22q11.21-q11.23 and is 
associated with cognitive decline and schizophrenia as well as with HAND [3, 
10, 20, 21]. CAG repeat loci on chromosome 22 are associated with 
schizophrenia and bipolar disorder at 22q11.2–q11.23 [22]. On chromosome 
22, two miRNAs are associated with schizophrenia- microRNA 130b and 
microRNA 301b [21]. Children with 22q11 deletions exhibit cognitive, motor, BIOINFORMATION  open access 
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and other neurological problems [23]. Emanuel syndrome is consequent to 
chromosome imbalance of a derivative chromosome 22 [der(22)] as a 
supernumerary chromosome with the following karyotype: 47, XX, 
+der(22)t(11;22) (q23;q11) in females or 47, XY, +der(22)t(11;22)(q23;q11) in 
males or, rarely, as well as a balanced (11; 22) translocation with the 
supernumerary derivative chromosome[24, 25]. Seizures are associated with a 
gene, seizure related 6 homolog (mouse)-like at 22q12.1 [21]. Cerebral 
gyration disorders (polymicrogyria) result from deletions in the 22q11 region 
[26]. This disorder is probably due to neuronal migrational dysfunction during 
development. Moreover, there are several additional genes on chromosome 22 
that involve processes already implicated in neuronal damage, to state a few, 
including aubiquitin pathway gene at 22q11.21, neurofilament heavy 
polypeptide at 22q12.2, and synaptosomal-associated protein at 22q11.21.[21]. 
 
In a previous study, we developed a hypothesis that coerced gene expression 
caused by treatment of neurons in culture with gp120, tat, and/or cocaine was 
deleterious for the neurons and that this resulted in the breakdown of natural 
barriers or firewalls that prevent expression spillover that could occur [27]. 
Thus, uninterrupted stimulation of gene expression could result in contiguously 
expressed genes that could be deleterious. This hypothesis was supported in a 
recent study on the evolutionary significance of contiguous gene expression, 
even up to five megabases apart, indicating that this was disadvantageous for 
the organism. Moreover, on an evolutionary time-scale one gene of each such 
pair of genes was likely to migrate from where it was originally located, to 
another portion of the genome [28]. This indicates a driving force reacting to an 
otherwise harmful condition. 
 
Conclusions and future directions: 
Two of seven genes that show changes in expression on chromosome 22 are 
involved in mental disease and may be involved in the pathogenesis of HAD 
and HIVE (compared to HIV+ patients). In addition to disruption of molecular 
gene expression-networks in these neurons, disruption of these and additional 
genes on this small chromosome may occur through mechanisms involving 
chromatin damage, remodeling, and miRNA. Along these lines, we 
hypothesize that coerced gene expression associated with chronic disease and 
persistent HIV-1 infection may result in disruption of gene expression control 
of contiguous genes. Moreover, under optimal conditions, genes that are in 
proximity that are undergoing gene expression, should be as far from each 
other as possible. Concisely, hotspots of gene expression are potential sites of 
disease association.  
 
The pathogenesis and treatment of neurological and neuropsychiatric diseases 
stemming from HIV-1 infection and subsequent invasion of the brain by HIV-1 
are being extensively studied. New treatment paradigms are in progress; 
however, much depends on the identification of the molecular mechanisms 
involved. Clearly, total inhibition of HIV-1 replication and development of 
HIV-1 vaccines are desirable goals, but yet unaccomplished. Therefore, it is 
important to develop novel paradigms of molecular analysis that reveal new 
areas for treatment of neurological and neuropsychiatric disease that result 
from HIV-1 brain infestation.  
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Supplementary material: 
 
Table 1: Allocation of Selected Genes to Chromosomes 
Chromosome  # of genes  # Allocated  # Expected  Chi Square p 
1 2968  23  18.38  1.28  0.2579
2 2288  15  14.17  0.05  0.8190
3 2032  9  12.58  1.09  0.2963
4 1297  7  8.03  0.14  0.7099
5 1643  7  10.18  1.04  0.3067
6 1963  6  12.16  3.32  0.0683
7 1443  12  8.94  1.10  0.2943
8 1127  9  6.98  0.61  0.4362
9 1299  5  8.04  1.20  0.2730
10 1440  13  8.92  1.96  0.1619
11 2093  9  12.96  1.30  0.2548
12 1652  12  10.23  0.32  0.5701
13 748  5  4.63  0.03  0.8628
14 1098  9  6.80  0.74  0.3906
15 1122  9  6.95  0.63  0.4282
16 1098  7  6.80  0.01  0.9378
17 1576  8  9.76  0.33  0.5633
18 766  3  4.74  0.66  0.4176
19 1454  9  9.00  0.00  0.9987
20 927  4  5.74  0.54  0.4608
21 303  2  1.88  0.01  0.9278
22 288  7  1.78  15.39  0.0001
X 1184  7  7.33  0.02  0.9003
Total 30625  190 197.00  -  - 
 
Table 2: Seven additional genes on Chromosome 22. [17, 18] 
CodeLink ID  GE ID  Alias  Chromosome 
22 location 
Function 
IDX 6580  GE519998  -  22q11.21  XM_498870 Hs.434330 
IDX 23200  GE61539  SMCR7L  22q13  Smith-Magenis syndrome chromosome region, candidate 7-like (SMCR7L) 
IDX 31250  GE726916  TBC1D22A  22q13.3  GTPase activator 
IDX 31404  GE729136  GGA1  22q13.31  protein binding and intracellular transporter,protein complex assembly, intra-Golgi transport, 
clathrin coat of trans-Golgi network vesicle, contains Alu repetitive element.  
IDX 41868  GE82723  DGCR8  22q11.2  double-stranded RNA and protein binding, DiGeorge syndrome critical region gene 8.  
IDX 48128  GE86394  CSNK1E  22q13.1  nucleotide binding, protein serine/threonine kinase activity, casein kinase I activity, protein-
tyrosine kinase activity, ATP binding, transferase activity, DNA repair, protein amino acid 
phosphorylation, signal transduction, casein kinase 1-epsilon-transcript variant 1 
IDX 51549  GE88364  MAPK11  22q13.33  nucleotide binding, protein serine/threonine kinase activity and cascade, MAP kinase activity, 
ATP binding, transferase activity, response to stress, signal transduction, antimicrobial 
humoral responsemitogen-activated protein kinase 11-transcript variant 1 
 
 
 
 